Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eldrin F Lewis

Showing results (201-210 of 213) with videos related to

Pageof 22
Sort By:
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JAMA|August 14, 2024
Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical TrialGervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, et al.
Lancet (London, England)|September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaiez Zannad, Christopher M O'Connor, Javed Butler, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
The New England Journal of Medicine|April 29, 2021
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKDGlenn M Chertow, Pablo E Pergola, Youssef M K Farag, et al.
Annals of the American Thoracic Society|September 10, 2025
Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF)Susan Redline, Dongdong Li, Shahrokh Javaheri, et al.
Circulation|October 9, 2023
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart AssociationChiadi E Ndumele, Ian J Neeland, Katherine R Tuttle, et al.
Circulation|October 9, 2023
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart AssociationChiadi E Ndumele, Janani Rangaswami, Sheryl L Chow, et al.
Journal of the American College of Cardiology|March 3, 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A Hicks, Kenneth W Mahaffey, Roxana Mehran, et al.
Pageof 22

Showing results (201-210 of 213) with videos related to

Sort By:
Pageof 22
Lancet (London, England)|September 2, 2025
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trialJaved Butler, Ciaran J McMullan, Kevin J Anstrom, et al.
European Heart Journal|August 30, 2025
Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trialJaved Butler, Francesco Fioretti, Ciaran J McMullan, et al.
JAMA|August 14, 2024
Edetate Disodium-Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical TrialGervasio A Lamas, Kevin J Anstrom, Ana Navas-Acien, et al.
Lancet (London, England)|September 2, 2025
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trialsFaiez Zannad, Christopher M O'Connor, Javed Butler, et al.
The New England Journal of Medicine|November 10, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial InfarctionMarc A Pfeffer, Brian Claggett, Eldrin F Lewis, et al.
The New England Journal of Medicine|April 29, 2021
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKDGlenn M Chertow, Pablo E Pergola, Youssef M K Farag, et al.
Annals of the American Thoracic Society|September 10, 2025
Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF)Susan Redline, Dongdong Li, Shahrokh Javaheri, et al.
Circulation|October 9, 2023
A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart AssociationChiadi E Ndumele, Ian J Neeland, Katherine R Tuttle, et al.
Circulation|October 9, 2023
Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart AssociationChiadi E Ndumele, Janani Rangaswami, Sheryl L Chow, et al.
Journal of the American College of Cardiology|March 3, 2018
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical TrialsKaren A Hicks, Kenneth W Mahaffey, Roxana Mehran, et al.
Pageof 22